Primary Site >> Colorectal Cancer
Gene >> CX3CL1
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
Ref: The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. PMID: 15586223 |
Ref: Polymorphisms of Fractalkine receptor CX3CR1 and plasma levels of its ligand CX3CL1 in colorectal cancer patients. PMID: 17611763 Ref: CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. PMID: 17621629 |
Ref: Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. PMID: 19909745 |
Ref: Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis. PMID: 24245985 |
Ref: Cystatin D locates in the nucleus at sites of active transcription and modulates gene and protein expression. PMID: 26364852 |
Ref: The Fractalkine-Receptor Axis Improves Human Colorectal Cancer Prognosis by Limiting Tumor Metastatic Dissemination. PMID: 26673138 Ref: Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. PMID: 27096098 |
Ref: Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. PMID: 28691930 Ref: Fractalkine (C-X3-C motif chemokine ligand 1) as a potential biomarker for depression and anxiety in colorectal cancer patients. PMID: 28804633 Ref: Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer. PMID: 28974887 |